Specialty drugmakers lobbying together

Here's a quandary: You're a good-sized drugmaker, but not a behemoth able to throw your weight around the industry's big trade associations. So how do you get your voice heard in our nation's capital? Form your own association, of course. That's exactly what Celgene, Cephalon, Cubist, Endo, Millennium, Purdue and Sepracor are doing: Banding together under the name America's Specialty Medicines Companies, and hiring a D.C. law firm for help getting organized.

What might this assortment's key issues be? That's unclear as yet. But you can bet we'll hear more from them as time goes by.

- read the item at In Vivo

Suggested Articles

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune…

Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.